| Abstract |
[Abstract] Objective: To explore the clinical efficacy of mirtazapine treatment in patients with Parkinsons disease (PD) and depression. Method: Case data were collected and filed from September 2021 to September 2022. The subjects were PD patients with depression admitted to the hospital, with a total of 80 cases included. The subjects were divided into a control group (treated with citalopram) and an observation group (treated with citalopram+mirtazapine) based on a 1:1 random number table method, with 40 cases in each group; Observe and compare the levels of anxiety and depression, sleep quality, Parkinsons disease unified rating scale (UPDRS - III), daily living ability, and incidence of adverse reactions between the two groups. Result: After treatment, the Hamilton Anxiety Scale (HAMA) and Hamilton Depression Scale (HAMD) scores of both groups decreased, and the observation group had lower scores (P<0.05); After treatment, the Pittsburgh Sleep Quality Index (PSQI) scores of both groups were significantly reduced, and the PSQI scores of the observation group were significantly lower than those of the control group (P<0.05); After treatment, the UPDRS - III scores of both groups decreased, while the Activity of Daily Living Scale (ADL) scores increased, and the observation group was better than the control group (P<0.05); Comparison of the incidence of adverse reactions between the two groups (P>0.05). Conclusion: The use of citalopram combined with mirtazapine in the treatment of PD patients with depression can exert good antidepressant effects, improve sleep quality, improve their psychological state, and have good medication safety.
|